Agency Information Collection Activities: Proposed Collection: Public Comment Request; Information Collection Request Title: Rapid Uptake of Disseminated Interventions (RUDI) Evaluation OMB No. 0915-xxxx-[New], 44371-44373 [2023-14772]
Download as PDF
<![CDATA[
lotter on DSK11XQN23PROD with NOTICES1
Federal Register / Vol. 88, No. 132 / Wednesday, July 12, 2023 / Notices
information on the cover sheet and not
in the body of your comments and you
must identify the information as
‘‘confidential.’’ Any information marked
as ‘‘confidential’’ will not be disclosed
except in accordance with 21 CFR 10.20
and other applicable disclosure law. For
more information about FDA’s posting
of comments to public dockets, see 80
FR 56469, September 18, 2015, or access
the information at: https://
www.govinfo.gov/content/pkg/FR-201509-18/pdf/2015-23389.pdf.
Docket: For access to the docket to
read background documents or the
electronic and written/paper comments
received, go to https://
www.regulations.gov and insert the
docket number, found in brackets in the
heading of this document, into the
‘‘Search’’ box and follow the prompts
and/or go to the Dockets Management
Staff, 5630 Fishers Lane, Rm. 1061,
Rockville, MD 20852, 240–402–7500.
FOR FURTHER INFORMATION CONTACT:
Jessica Seo, Center for Drug Evaluation
and Research, Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg. 31, Rm. 2417, Silver Spring,
MD 20993–0002, 301–796–7699, email:
NDAC@fda.hhs.gov, or FDA Advisory
Committee Information Line, 1–800–
741–8138 (301–443–0572 in the
Washington, DC area). A notice in the
Federal Register about last-minute
modifications that impact a previously
announced advisory committee meeting
cannot always be published quickly
enough to provide timely notice.
Therefore, you should always check
FDA’s website at https://www.fda.gov/
AdvisoryCommittees/default.htm and
scroll down to the appropriate advisory
committee meeting link, or call the
advisory committee information line to
learn about possible modifications
before the meeting.
SUPPLEMENTARY INFORMATION:
Agenda: The meeting presentations
will be heard, viewed, captioned, and
recorded through an online
teleconferencing and/or video
conferencing platform. The Committee
will discuss new data regarding the
‘Generally Recognized as Safe and
Effective’ (GRASE) status of oral
phenylephrine as a nasal decongestant
that have become available since FDA
last examined the issue.
FDA intends to make background
material available to the public no later
than 2 business days before the meeting.
If FDA is unable to post the background
material on its website prior to the
meeting, the background material will
be made publicly available on FDA’s
website at the time of the advisory
committee meeting. Background
VerDate Sep<11>2014
17:29 Jul 11, 2023
Jkt 259001
material and the link to the online
teleconference and/or video conference
meeting will be available at https://
www.fda.gov/AdvisoryCommittees/
Calendar/default.htm. Scroll down to
the appropriate advisory committee
meeting link. The meeting will include
slide presentations with audio and
video components to allow the
presentation of materials in a manner
that most closely resembles an in-person
advisory committee meeting.
Procedure: Interested persons may
present data, information, or views,
orally or in writing, on issues pending
before the Committee. All electronic and
written submissions submitted to the
Docket (see ADDRESSES) on or before
August 25, 2023, will be provided to the
Committee. Oral presentations from the
public will be scheduled between
approximately 4 p.m. and 5:30 p.m.
Eastern Time on September 11, 2023.
Those individuals interested in making
formal oral presentations should notify
the contact person and submit a brief
statement of the general nature of the
evidence or arguments they wish to
present, the names and addresses of
proposed participants, and an
indication of the approximate time
requested to make their presentation on
or before August 17, 2023. Time allotted
for each presentation may be limited. If
the number of registrants requesting to
speak is greater than can be reasonably
accommodated during the scheduled
open public hearing session, FDA may
conduct a lottery to determine the
speakers for the scheduled open public
hearing session. The contact person will
notify interested persons regarding their
request to speak by August 18, 2023.
For press inquiries, please contact the
Office of Media Affairs at fdaoma@
fda.hhs.gov or 301–796–4540.
FDA welcomes the attendance of the
public at its advisory committee
meetings and will make every effort to
accommodate persons with disabilities.
If you require accommodations due to a
disability, please contact Jessica Seo
(see FOR FURTHER INFORMATION CONTACT)
at least 7 days in advance of the
meeting.
FDA is committed to the orderly
conduct of its advisory committee
meetings. Please visit our website at
https://www.fda.gov/
AdvisoryCommittees/
AboutAdvisoryCommittees/
ucm111462.htm for procedures on
public conduct during advisory
committee meetings.
Notice of this meeting is given under
the Federal Advisory Committee Act (5
U.S.C. 1001 et seq.). This meeting notice
also serves as notice that, pursuant to 21
CFR 10.19, the requirements in 21 CFR
PO 00000
Frm 00122
Fmt 4703
Sfmt 4703
44371
14.22(b), (f), and (g) relating to the
location of advisory committee meetings
are hereby waived to allow for this
meeting to take place using an online
meeting platform. This waiver is in the
interest of allowing greater transparency
and opportunities for public
participation, in addition to
convenience for advisory committee
members, speakers, and guest speakers.
No participant will be prejudiced by
this waiver, and that the ends of justice
will be served by allowing for this
modification to FDA’s advisory
committee meeting procedures.
Dated: July 6, 2023.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2023–14713 Filed 7–11–23; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Health Resources and Services
Administration
Agency Information Collection
Activities: Proposed Collection: Public
Comment Request; Information
Collection Request Title: Rapid Uptake
of Disseminated Interventions (RUDI)
Evaluation OMB No. 0915–xxxx—[New]
Health Resources and Services
Administration (HRSA), Department of
Health and Human Services.
ACTION: Notice.
AGENCY:
In compliance with the
requirement for opportunity for public
comment on proposed data collection
projects of the Paperwork Reduction Act
of 1995, HRSA announces plans to
submit an Information Collection
Request (ICR), described below, to the
Office of Management and Budget
(OMB). Prior to submitting the ICR to
OMB, HRSA seeks comments from the
public regarding the burden estimate,
below, or any other aspect of the ICR.
DATES: Comments on this ICR should be
received no later than September 11,
2023.
SUMMARY:
Submit your comments to
paperwork@hrsa.gov or mail the HRSA
Information Collection Clearance
Officer, Room 14N39, 5600 Fishers
Lane, Rockville, Maryland 20857.
FOR FURTHER INFORMATION CONTACT: To
request more information on the
proposed project or to obtain a copy of
the data collection plans and draft
instruments, email paperwork@hrsa.gov
or call Samantha Miller, the HRSA
Information Collection Clearance
Officer, at (301) 443–3983.
ADDRESSES:
E:\FR\FM\12JYN1.SGM
12JYN1
44372
Federal Register / Vol. 88, No. 132 / Wednesday, July 12, 2023 / Notices
When
submitting comments or requesting
information, please include the ICR title
for reference.
Information Collection Request Title:
Rapid Uptake of Disseminated
Interventions (RUDI) Evaluation OMB
No. 0915–xxxx—[New].
Abstract: HRSA has dedicated
significant resources and effort to
developing novel intervention strategies
aimed at eliminating disparities and
improving HIV-related health outcomes
for people with HIV. HRSA encourages
and supports Ryan White HIV/AIDS
Program (RWHAP) providers to
implement interventions developed
through its Special Projects of National
Significance (RWHAP Part F SPNS)
program and technical assistance
initiatives that have been found to be
effective, with adaptations for priority
populations served as applicable. HRSA
disseminates its RWHAP Part F SPNS
and technical assistance initiative
resources and products across a variety
of dissemination channels, hoping to
reach a maximum number of RWHAP
recipients and subrecipients for whom
these resources may meet an important
need. This mixed-methods Rapid
Uptake of Disseminated Interventions
(RUDI) evaluation will use a web-based
survey and virtual site visits to collect
information from RWHAP recipients
and subrecipients on the uptake, utility,
and efficacy of the resources and
products HRSA disseminates; the
effectiveness of its dissemination
processes; and the reach of its
dissemination channels. HRSA will use
the information to identify
opportunities for strengthening its
dissemination channels and resources to
improve care and health outcomes for
program participants.
Need and Proposed Use of the
Information: Currently, HRSA does not
SUPPLEMENTARY INFORMATION:
systematically gather information about
the resources accessed by RWHAP
providers, RWHAP recipients, or AIDS
Education and Training Center (AETC)
staff and the extent to which they use
those resources to inform
implementation of interventions.
The mixed-methods RUDI evaluation
will help HRSA systematically assess
and understand (1) how, where, and
why recipients of RWHAP funding
access and use its disseminated
resources and products; and (2) the
utility and effectiveness of the
disseminated resources and products in
caring for and treating people with HIV.
HRSA will use the findings from the
RUDI evaluation to develop strategies to
maximize the uptake and impact of its
disseminated resources and products,
contributing to ending the HIV epidemic
in the United States.
Likely Respondents: The mixedmethods RUDI evaluation includes a
web-based survey of all RWHAP
recipients and subrecipients nationally,
individual interviews with a sample of
RWHAP recipients, virtual site visits
with a sample of RWHAP providers, and
individual interviews with all AETCs.
The RUDI web-based survey design
includes two versions of the survey that
will be administered to non-overlapping
respondents—the RUDI Recipients
Survey for RWHAP Part A and B
recipient administrative entities—and
the RUDI Providers Survey for Part A
and B subrecipients and Part C, D, and
F recipients who provide direct care.
Both versions ask about respondents’
use of HRSA-disseminated resources,
how they were helpful, what could be
improved, and reasons for non-use
where applicable. In addition, the RUDI
Recipients Survey asks about the
recipients’ role in guiding their
subrecipients to needed resources, and
the RUDI Providers Survey asks about
the recipients’ experience implementing
interventions for which they used the
resources. Both surveys are designed to
be followed up with additional sets of
interviews with a sample of the survey
respondents to provide deeper
understanding of their experience to
support development of actionable
recommendations pertaining to
dissemination. Virtual site visits to
RWHAP providers include interviews
with an average of three staff within
each provider organization that were
part of an intervention implementation
with assistance from HRSA resources.
Individual interviews for Part A and B
recipient administrative entities and
AETCs will generate a complete picture
of how those organizations use HRSA
resources and how the resources or their
dissemination could be improved for
the future, especially when considered
together with the survey responses and
virtual site visit data from the RWHAP
providers.
Burden Statement: Burden in the
context of this study means the time
that persons expend to generate,
maintain, retain, disclose, and provide
the requested information. This
includes the time needed to review
instructions; to develop, acquire, install,
and utilize technology and systems for
the purpose of collecting, validating,
and verifying information, processing
and maintaining information, and
disclosing and providing information; to
train personnel and to be able to
respond to a collection of information;
to search data sources; to complete and
review the collection of information;
and to transmit or otherwise disclose
the information. The total annual
burden hours estimated for this ICR are
summarized in the table below.
TOTAL ESTIMATED ANNUALIZED BURDEN HOURS
Number of
respondents
Form name
lotter on DSK11XQN23PROD with NOTICES1
RUDI Recipient Survey ........................................................
RUDI Provider Survey .........................................................
Interviews .............................................................................
Virtual site visit interviews ....................................................
Interviews AETCs ................................................................
HRSA specifically requests comments
on (1) the necessity and utility of the
proposed information collection for the
proper performance of the agency’s
functions, (2) the accuracy of the
VerDate Sep<11>2014
17:29 Jul 11, 2023
Jkt 259001
56
1,066
20
40
8
1,190
Number of
responses per
respondent
1
1
2
3
1
........................
estimated burden, (3) ways to enhance
the quality, utility, and clarity of the
information to be collected, and (4) the
use of automated collection techniques
or other forms of information
PO 00000
Frm 00123
Fmt 4703
Total
responses
Sfmt 4703
56
1,066
40
120
8
1,290
Average
burden per
response
(in hours)
.25
.25
.75
1.00
1.00
........................
Total burden
hours
14
266.5
30
120
8
438.5
technology to minimize the information
collection burden.
E:\FR\FM\12JYN1.SGM
12JYN1
Federal Register / Vol. 88, No. 132 / Wednesday, July 12, 2023 / Notices
Maria G. Button,
Director, Executive Secretariat.
[FR Doc. 2023–14772 Filed 7–11–23; 8:45 am]
BILLING CODE 4165–15–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Health Resources and Services
Administration
National Vaccine Injury Compensation
Program; List of Petitions Received
Health Resources and Services
Administration (HRSA), Department of
Health and Human Services (HHS).
ACTION: Notice.
AGENCY:
HRSA is publishing this
notice of petitions received under the
National Vaccine Injury Compensation
Program (the Program), as required by
the Public Health Service (PHS) Act, as
amended. While the Secretary of HHS is
named as the respondent in all
proceedings brought by the filing of
petitions for compensation under the
Program, the United States Court of
Federal Claims is charged by statute
with responsibility for considering and
acting upon the petitions.
FOR FURTHER INFORMATION CONTACT: For
information about requirements for
filing petitions, and the Program in
general, contact Lisa L. Reyes, Clerk of
Court, United States Court of Federal
Claims, 717 Madison Place NW,
Washington, DC 20005, (202) 357–6400.
For information on HRSA’s role in the
Program, contact the Director, National
Vaccine Injury Compensation Program,
5600 Fishers Lane, Room 08N146B,
Rockville, Maryland 20857; (301) 443–
6593, or visit our website at: https://
www.hrsa.gov/vaccinecompensation/
index.html.
SUMMARY:
The
Program provides a system of no-fault
compensation for certain individuals
who have been injured by specified
childhood vaccines. Subtitle 2 of Title
XXI of the PHS Act, 42 U.S.C. 300aa–
10 et seq., provides that those seeking
compensation are to file a petition with
the United States Court of Federal
Claims and to serve a copy of the
petition to the Secretary of HHS, who is
named as the respondent in each
proceeding. The Secretary has delegated
this responsibility under the Program to
HRSA. The Court is directed by statute
to appoint special masters who take
evidence, conduct hearings as
appropriate, and make initial decisions
as to eligibility for, and amount of,
compensation.
lotter on DSK11XQN23PROD with NOTICES1
SUPPLEMENTARY INFORMATION:
VerDate Sep<11>2014
17:29 Jul 11, 2023
Jkt 259001
A petition may be filed with respect
to injuries, disabilities, illnesses,
conditions, and deaths resulting from
vaccines described in the Vaccine Injury
Table (the Table) set forth at 42 CFR
100.3. This Table lists for each covered
childhood vaccine the conditions that
may lead to compensation and, for each
condition, the time period for
occurrence of the first symptom or
manifestation of onset or of significant
aggravation after vaccine
administration. Compensation may also
be awarded for conditions not listed in
the Table and for conditions that are
manifested outside the time periods
specified in the Table, but only if the
petitioner shows that the condition was
caused by one of the listed vaccines.
Section 2112(b)(2) of the PHS Act, 42
U.S.C. 300aa–12(b)(2), requires that
‘‘[w]ithin 30 days after the Secretary
receives service of any petition filed
under section 2111 the Secretary shall
publish notice of such petition in the
Federal Register.’’ Set forth below is a
list of petitions received by HRSA on
May 1, 2023, through May 31, 2023.
This list provides the name of the
petitioner, city, and state of vaccination
(if unknown then the city and state of
the person or attorney filing the claim),
and case number. In cases where the
Court has redacted the name of a
petitioner and/or the case number, the
list reflects such redaction.
Section 2112(b)(2) also provides that
the special master ‘‘shall afford all
interested persons an opportunity to
submit relevant, written information’’
relating to the following:
1. The existence of evidence ‘‘that
there is not a preponderance of the
evidence that the illness, disability,
injury, condition, or death described in
the petition is due to factors unrelated
to the administration of the vaccine
described in the petition,’’ and
2. Any allegation in a petition that the
petitioner either:
a. ‘‘[S]ustained, or had significantly
aggravated, any illness, disability,
injury, or condition not set forth in the
Vaccine Injury Table, but which was
caused by’’ one of the vaccines referred
to in the Table, or
b. ‘‘[S]ustained, or had significantly
aggravated, any illness, disability,
injury, or condition set forth in the
Vaccine Injury Table the first symptom
or manifestation of the onset or
significant aggravation of which did not
occur within the time period set forth in
the Table, but which was caused by a
vaccine’’ referred to in the Table.
In accordance with Section
2112(b)(2), all interested persons may
submit written information relevant to
the issues described above in the case of
PO 00000
Frm 00124
Fmt 4703
Sfmt 4703
44373
the petitions listed below. Any person
choosing to do so should file an original
and three (3) copies of the information
with the Clerk of the United States
Court of Federal Claims at the address
listed above (under the heading FOR
FURTHER INFORMATION CONTACT), with a
copy to HRSA addressed to Director,
Division of Injury Compensation
Programs, Health Systems Bureau, 5600
Fishers Lane, 08N146B, Rockville,
Maryland 20857. The Court’s caption
(Petitioner’s Name v. Secretary of HHS)
and the docket number assigned to the
petition should be used as the caption
for the written submission. Chapter 35
of Title 44, United States Code, related
to paperwork reduction, does not apply
to information required for purposes of
carrying out the Program.
Carole Johnson,
Administrator.
List of Petitions Filed
1. Delshun Carter, Waupun, Wisconsin, Court
of Federal Claims No: 23–0618V
2. Tommie Lee Lanier, Statesboro, Georgia,
Court of Federal Claims No: 23–0624V
3. Haley Petz, Clarks Summit, Pennsylvania,
Court of Federal Claims No: 23–0625V
4. Denise Bernhang on behalf of B. B., Boca
Raton, Florida, Court of Federal Claims
No: 23–0627V
5. Torri Kidder, Plaquemine, Louisiana,
Court of Federal Claims No: 23–0628V
6. Tessa Needham, Portland, Oregon, Court of
Federal Claims No: 23–0630V
7. Lyndzee Weiss, Phoenix, Arizona, Court of
Federal Claims No: 23–0633V
8. Mikako Welborn, Springfield, Oregon,
Court of Federal Claims No: 23–0635V
9. Sangeetha Gnanasundaram, Colorado
Springs, Colorado, Court of Federal
Claims No: 23–0636V
10. Erica Jennings, Tupelo, Mississippi, Court
of Federal Claims No: 23–0637V
11. Daisy Santiago, San Diego, California,
Court of Federal Claims No: 23–0640V
12. Edith Fox, La Luz, New Mexico, Court of
Federal Claims No: 23–0646V
13. Ranaye Goff, Luck, Wisconsin, Court of
Federal Claims No: 23–0649V
14. Douglas Eberline, Peoria, Arizona, Court
of Federal Claims No: 23–0655V
15. Sharee Barber on behalf of A. B.,
Medford, Oregon, Court of Federal
Claims No: 23–0657V
16. Michelle Palazzolo, Staten Island, New
York, Court of Federal Claims No: 23–
0658V
17. Timothy Johnnies, Waupun, Wisconsin,
Court of Federal Claims No: 23–0659V
18. Terry Cooper, Lewisburg, Pennsylvania,
Court of Federal Claims No: 23–0661V
19. Tuipine Sofara, San Bruno, California,
Court of Federal Claims No: 23–0662V
20. Veronica Madden, North Weymouth,
Massachusetts, Court of Federal Claims
No: 23–0665V
21. Carissa Photopoulos on behalf of Steven
Wedekind, Deceased, Clintonville,
Wisconsin, Court of Federal Claims No:
23–0667V
E:\FR\FM\12JYN1.SGM
12JYN1
]]>Agencies
[Federal Register Volume 88, Number 132 (Wednesday, July 12, 2023)]
[Notices]
[Pages 44371-44373]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-14772]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Health Resources and Services Administration
Agency Information Collection Activities: Proposed Collection:
Public Comment Request; Information Collection Request Title: Rapid
Uptake of Disseminated Interventions (RUDI) Evaluation OMB No. 0915-
xxxx--[New]
AGENCY: Health Resources and Services Administration (HRSA), Department
of Health and Human Services.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: In compliance with the requirement for opportunity for public
comment on proposed data collection projects of the Paperwork Reduction
Act of 1995, HRSA announces plans to submit an Information Collection
Request (ICR), described below, to the Office of Management and Budget
(OMB). Prior to submitting the ICR to OMB, HRSA seeks comments from the
public regarding the burden estimate, below, or any other aspect of the
ICR.
DATES: Comments on this ICR should be received no later than September
11, 2023.
ADDRESSES: Submit your comments to [email protected] or mail the HRSA
Information Collection Clearance Officer, Room 14N39, 5600 Fishers
Lane, Rockville, Maryland 20857.
FOR FURTHER INFORMATION CONTACT: To request more information on the
proposed project or to obtain a copy of the data collection plans and
draft instruments, email [email protected] or call Samantha Miller,
the HRSA Information Collection Clearance Officer, at (301) 443-3983.
[[Page 44372]]
SUPPLEMENTARY INFORMATION: When submitting comments or requesting
information, please include the ICR title for reference.
Information Collection Request Title: Rapid Uptake of Disseminated
Interventions (RUDI) Evaluation OMB No. 0915-xxxx--[New].
Abstract: HRSA has dedicated significant resources and effort to
developing novel intervention strategies aimed at eliminating
disparities and improving HIV-related health outcomes for people with
HIV. HRSA encourages and supports Ryan White HIV/AIDS Program (RWHAP)
providers to implement interventions developed through its Special
Projects of National Significance (RWHAP Part F SPNS) program and
technical assistance initiatives that have been found to be effective,
with adaptations for priority populations served as applicable. HRSA
disseminates its RWHAP Part F SPNS and technical assistance initiative
resources and products across a variety of dissemination channels,
hoping to reach a maximum number of RWHAP recipients and subrecipients
for whom these resources may meet an important need. This mixed-methods
Rapid Uptake of Disseminated Interventions (RUDI) evaluation will use a
web-based survey and virtual site visits to collect information from
RWHAP recipients and subrecipients on the uptake, utility, and efficacy
of the resources and products HRSA disseminates; the effectiveness of
its dissemination processes; and the reach of its dissemination
channels. HRSA will use the information to identify opportunities for
strengthening its dissemination channels and resources to improve care
and health outcomes for program participants.
Need and Proposed Use of the Information: Currently, HRSA does not
systematically gather information about the resources accessed by RWHAP
providers, RWHAP recipients, or AIDS Education and Training Center
(AETC) staff and the extent to which they use those resources to inform
implementation of interventions.
The mixed-methods RUDI evaluation will help HRSA systematically
assess and understand (1) how, where, and why recipients of RWHAP
funding access and use its disseminated resources and products; and (2)
the utility and effectiveness of the disseminated resources and
products in caring for and treating people with HIV. HRSA will use the
findings from the RUDI evaluation to develop strategies to maximize the
uptake and impact of its disseminated resources and products,
contributing to ending the HIV epidemic in the United States.
Likely Respondents: The mixed-methods RUDI evaluation includes a
web-based survey of all RWHAP recipients and subrecipients nationally,
individual interviews with a sample of RWHAP recipients, virtual site
visits with a sample of RWHAP providers, and individual interviews with
all AETCs. The RUDI web-based survey design includes two versions of
the survey that will be administered to non-overlapping respondents--
the RUDI Recipients Survey for RWHAP Part A and B recipient
administrative entities--and the RUDI Providers Survey for Part A and B
subrecipients and Part C, D, and F recipients who provide direct care.
Both versions ask about respondents' use of HRSA-disseminated
resources, how they were helpful, what could be improved, and reasons
for non-use where applicable. In addition, the RUDI Recipients Survey
asks about the recipients' role in guiding their subrecipients to
needed resources, and the RUDI Providers Survey asks about the
recipients' experience implementing interventions for which they used
the resources. Both surveys are designed to be followed up with
additional sets of interviews with a sample of the survey respondents
to provide deeper understanding of their experience to support
development of actionable recommendations pertaining to dissemination.
Virtual site visits to RWHAP providers include interviews with an
average of three staff within each provider organization that were part
of an intervention implementation with assistance from HRSA resources.
Individual interviews for Part A and B recipient administrative
entities and AETCs will generate a complete picture of how those
organizations use HRSA resources and how the resources or their
dissemination could be improved for the future, especially when
considered together with the survey responses and virtual site visit
data from the RWHAP providers.
Burden Statement: Burden in the context of this study means the
time that persons expend to generate, maintain, retain, disclose, and
provide the requested information. This includes the time needed to
review instructions; to develop, acquire, install, and utilize
technology and systems for the purpose of collecting, validating, and
verifying information, processing and maintaining information, and
disclosing and providing information; to train personnel and to be able
to respond to a collection of information; to search data sources; to
complete and review the collection of information; and to transmit or
otherwise disclose the information. The total annual burden hours
estimated for this ICR are summarized in the table below.
Total Estimated Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
Average
Number of Number of Total burden per Total burden
Form name respondents responses per responses response (in hours
respondent hours)
----------------------------------------------------------------------------------------------------------------
RUDI Recipient Survey........... 56 1 56 .25 14
RUDI Provider Survey............ 1,066 1 1,066 .25 266.5
Interviews...................... 20 2 40 .75 30
Virtual site visit interviews... 40 3 120 1.00 120
Interviews AETCs................ 8 1 8 1.00 8
1,190 .............. 1,290 .............. 438.5
----------------------------------------------------------------------------------------------------------------
HRSA specifically requests comments on (1) the necessity and
utility of the proposed information collection for the proper
performance of the agency's functions, (2) the accuracy of the
estimated burden, (3) ways to enhance the quality, utility, and clarity
of the information to be collected, and (4) the use of automated
collection techniques or other forms of information technology to
minimize the information collection burden.
[[Page 44373]]
Maria G. Button,
Director, Executive Secretariat.
[FR Doc. 2023-14772 Filed 7-11-23; 8:45 am]
BILLING CODE 4165-15-P
